일본뇌염백신 CJ-50003의 일반약리작용 = General Pharmacology of CJ-50003, A Vaccine Against Japanese Encephalitis

다국어 초록 (Multilingual Abstract)

To develop the second generation Japanese encephalitis (JE) vaccine, an attenuated JE vaccine virus strain SA14-14-2 (PDK) was adapted to Vero cell. The resulting virus SA14-14-2 (Vero) was purified using sucrose density gradient, inactivated with formalin and mixed with alum hydroxide to prepare the test vaccine named CJ-50003. The general pharmacological properties of CJ-50003 were evaluated in mice, rats, dogs and isolated guinea pig ileum. The doses were 0.16~ 16 ㎍/kg i.m. for mice and rats and 0.48-1.6 ㎍/kg i.v. for dogs. The concentration of 0.0016-0.16 mg/ml were used for the assay with guinea pig ileum. lntramuscular administration of CJ-50003 at the doses did not alter general behavior and the responses for central nervous system, smooth muscles, gastrointestinal system, cardiovascular and respiratory system and water and electrolytes excretion. In summary, CJ-50003 had no pharmacological effect in these studies even up to the 100-fold of the expected clinical dose, 5 ㎍/man/30 kg.

목차 (Table of Contents)

• ABSTRACT
  
• Ⅰ. 서론
  
• Ⅱ. 실험재료 및 방법
  
• Ⅲ. 시험 결과
  
• Ⅳ. 고찰
  
• 참고문헌